Journal

The Journal of Sexual Medicine

Papers (8)

Sexual Morbidity Assessment in Gyne-Oncology Follow-Up: Development of the Sexual Well-Being After Cervical or Endometrial Cancer (SWELL-CE) Patient-Reported Outcome Measure

Abstract Background Clinical assessment and management of sexual difficulties after gynecological cancer remain a neglected aspect of women’s rehabilitation. Aim To develop and validate a patient-reported outcome measure of sexual well-being for women experiencing sexual consequences of cervical and endometrial cancer treatment for use in routine follow-up. Methods This is a sequential mixed method study comprising (i) in-depth qualitative interviews (n=21 of 118) to generate items regarding sexual consequences of cervical or endometrial cancer and treatment; (ii) questionnaire construction with 51 core items (all respondents) and 4 subsections (18–58 items), depending on the relationship status and whether or not participants were sexually active (SA/NSA); (iii) item refinement following cognitive debriefing (n=13 of 21); (iv) validation of resultant items via postal survey (n=788 women) and Rasch analysis; and (v) creation of brief (14-item) clinical screener. Women attending routine follow-up (3 months to 5 years) at 6 English cancer centers and members of 3 UK cancer patient websites, who met the study inclusion criteria, were invited to participate. Outcomes The primary outcome of this study was the construction and initial psychometric testing of SWELL-CE short and long form versions. Results 21 women participated in interviews and 250 of 788 (32%) returned the postal survey (T1). 110 draft items were evaluated using cognitive testing (n=13) to refine instrument design and test face validity, comprehension, and acceptability. Exploratory factor analysis of survey data (n=250) produced an initial 6 domain structure as a guidance for the Rasch analysis. Subsequent Rasch analysis yielded a 3 domain structure: physical sexual function, sexual and relationship concerns, and sexual desire and sexual self-esteem, each satisfying Rasch model requirements within their respective SA (item pool =59) and NSA (item pool =53) categories, including the absence of local response dependency and all showing strict unidimensionality. The 3 subscales demonstrated good psychometric properties, external validity, and test-retest reliability. A valid Rasch short form of 14 items was created from the larger item pool. Clinical Implications This PROM may assist clinicians to improve identification, discussion, and management of women who could benefit from sexual rehabilitation. Strengths & Limitations Initial evaluation supports psychometric validity and reliability in the assessment of physical sexual function, sexual interest and sexual self-esteem, and sexual and relationship concerns in this study sample. However, given this study’s modest response rate (32%, n=250), findings should be interpreted with caution. This PROM identifies sexual concerns in women who are sexually active or sexually non-active due to illness or treatment-associated sexual difficulties. Conclusion Sexual Well-being after Cervical or Endometrial Cancer is a novel and psychometrically valid sexual well-being measure for clinical assessment of female sexual difficulties after cervical or endometrial cancer treatment.

Comparative efficacy of non-ablative radiofrequency and promestriene in management of the genitourinary syndrome and sexual dysfunction in cervical cancer survivors: a pilot randomized trial

Abstract Background Radiotherapy for cervical cancer can lead to genitourinary syndrome (GUS), which negatively impacts sexual function and the quality of life among female cancer survivors. Objective To evaluate the efficacy of promestriene and non-ablative radiofrequency (NARF) in treating GUS and its effects on sexual function in women who have undergone radiotherapy for cervical cancer (CC). Method In this pilot randomized clinical trial included 24 women who had received radiotherapy and/or brachytherapy for CC within the past five years. Participants were randomized to receive treatment with promestriene cream or intravaginal (NARF). Sexual function was assessed pre- and post-treatment using the Female Sexual Function Index (FSFI). Vaginal symptoms were evaluated using a visual analog scale (VAS), and histological analyses of vaginal biopsies were performed before and after the intervention. Outcomes The main outcomes measured were improvements in sexual function and reductions in vaginal symptoms. Results Significant improvements in FSFI scores and reductions in vaginal symptom intensity were observed in both treatment groups. The median FSFI score increased from 13.0 to 23.1 after treatment. Histological analysis demonstrated a significant increase in epithelial thickness and an improvement in stromal quality in both groups. No significant differences were noted between the promestriene and (NARF) groups concerning sexual function improvements or symptom reduction. Clinical Implications Both promestriene and (NARF) proved effective and safe enhancing sexual function and reducing vaginal symptoms in post-radiotherapy CC survivors. Strengths and Limitations The study’s strengths include its randomized design and comprehensive assessment of subjective and objective outcomes. However, the small sample size and limited follow-up period limit the generalization and long-term applicability of the findings. Conclusion Both promestriene and (NARF) significantly improve sexual function and alleviate vaginal symptoms in women treated with radiotherapy for CC, presenting viable options for managing GUS in this patient population.

Associations between gynecologic clinician type and routine female sexual dysfunction screening

Abstract Background Female sexual dysfunction (FSD) is a common problem in the United States; however, only 14% to 40% of women are screened by their health care clinicians. There are few data on how differences in clinician type affects screening rates. Aim This study aimed to assess differences in FSD screening rates among gynecology clinician types, identify factors associated with screening, and compare screening rates of FSD against conditions with established screening recommendations. Methods Data were collected by retrospective chart review of annual visits at an urban tertiary care center. Screening rates for FSD, depression, cervical cancer, and breast cancer were calculated and compared. Multivariable logistic regression modeling was utilized to assess the correlation between various patient characteristics and FSD screening rates. Outcomes Study outcome measures included percentages of women who were screened for FSD, depression, cervical cancer, and breast cancer. Results FSD screening rate was significantly higher among resident-level clinicians vs nonresident clinicians (59% vs 31%; P < .001). When the nonresident clinicians were subanalyzed, certified nursing midwives were the second most likely to screen for FSD (odds ratio [OR], 0.41), followed by nurse practitioners (OR, 0.29) and attending physicians (OR, 0.22). According to multivariable logistic regression techniques, 5 factors were associated with an increased likelihood of a patient being screened for FSD at an annual examination: patient seen by a resident physician rather than an attending physician, patient history of FSD, patient age ≥40 years, patient report of being sexually active at the time of visit, and patient history of cervical procedures. Clinical Implications There is an opportunity to improve FSD screening rates by clinicians. Future research may assess what factors, such as increased sexual function education or greater incentives to document FSD screening, may result in higher screening rates. From this, targeted and effective interventions might be crafted to improve future screening rates. Strengths and Limitations This study is one of the first to compare FSD screening rates among clinician types in the same specialty. Study limitations include the inherent limitations of a retrospective design, including selection biases. Conclusion Residents were more likely to screen for FSD at annual well-woman visits than attending clinicians, nurse practitioners, and certified nurse midwives. Understanding the reasons for varied FSD screening rates among clinician types may aid in the development of strategies to improve screening for this important aspect of women’s health.

Long-term Quality of Life and Sexual Function After Neoadjuvant Chemotherapy and Radical Surgery for Locally Advanced Cervical Cancer

ABSTRACTBackgroundCervical cancer survivors report the worst quality of life (QoL) among all cancer survivors and this is mainly due to their younger age and the long-term treatment sequelae.AimThe purpose of this study is to assess the long-term QoL and sexual function of locally advanced cervical cancer (LACC) patients treated with neoadjuvant chemotherapy (NACT) and radical hysterectomy (RH) instead of the standard chemoradiotherapy.MethodsThis is a retrospective case-control study including LACC patients (FIGO stage IIB-IVA) treated with the NACT-RH strategy and a control group of healthy women undergoing hysterectomy for uterine fibromatosis in the same period.OutcomesMain outcome measures were the EORTC QLQ-C30 and EORTC QLQ-CX24 for quality of life and Female Sexual Function Index (FSFI) for sexual function.ResultsOverall, 96 patients were included: 48 LACC and 48 controls. The mean age at diagnosis was 45.5 ± 9.0 and 47.0 ± 7.8, respectively (P = .38). Compared to controls, LACC patients reported lower mean scores for the global health status (69.4 ± 22.6 vs 81.2 ± 24.3; Mean Difference (MD): -11.80 [95% CI: -21.19, -2.41]; P = .016), QLQ-C30 functional scale (80.1 ± 22.6 vs 92.4 ± 14.9; MD: -12.30 [95% CI: -19.96, -4.64]; P = .002), QLQ-Cx24 functional scale (55.5 ± 25.0 vs 80.4 ± 22.4; MD: -24.00 [95% CI: -34.40, -15.40]; P < .001), and the total FSFI (19.3 ± 9.6 vs 26.2 ± 9.9; MD: -6.90 [95% CI: -10.80, -3.00]; P < .001). On the other hand, LACC patients reported higher mean scores on the QLQ-C30 (16.9 ± 22.1 vs 8.4 ± 16.6; MD: 8.50 [95% CI: 0.68, 16.32]; P = .03) and QLQ-CX24 (26.0 ± 28.8 vs 15.0 ± 11.7; MD: 11.00 [95% CI: -2.21, 19.79]; P = .01) symptoms scales.Clinical implicationsThe confirmed poor quality of life even in surgically treated LACC survivors underlines the importance of tailoring parametrectomy based on lymph node status and developing personalized strategies.Strengths and limitationsThe study assessed the long-term QoL and sexual function in the specific subpopulation of LACC patients treated with NACT-RH. Main limitations include the small sample size and the retrospective design.ConclusionLACC long-term survivors treated with NACT-RH experience poor QoL and sexual dysfunction.

Sexual functioning after risk-reducing oophorectomy: a prospective study

Abstract Background Several studies have suggested a decrease in sexual function after risk-reducing salpingo-oophorectomy (RRSO) that is not mitigated by hormone therapy treatment. Aims This is a prospective cohort study of women followed from the time of diagnosis, including those who chose whether to proceed with RRSO, and changes in sexual function. Methods Premenopausal women were recruited from a high-risk cancer genetics clinic at a large academic center and completed detailed demographics and validated measures regarding their physical, mental, and sexual health. Outcomes Women were surveyed over the course of 60 months, using the Sexual Health Outcomes in Women Questionnaire (SHOW-Q), and results were analyzed, controlling for known confounders in sexual health, comparing women with and without RRSO. Results One hundred women completed the study, 99 of whom completed baseline SHOW-Q surveys. Forty-one women planned RRSO at the beginning of the study, and another 30 underwent an RRSO during the study period. At baseline, women who underwent RRSO had lower sexual functioning scores in terms of sexual satisfaction and pelvic problem interface. Over 60 months, there was no difference in sexual function scores between the RRSO and the no-RRSO group in multivariable models that adjusted for depression, hormone use, menopausal symptoms, or other confounders. Clinical Implications Pre-surgery sexual function predicts post-surgery sexual function, which challenges existing dogma, and women can be reassured that surgery likely won’t affect sexual function. Strengths and Limitations This study’s strength was the relatively large sample size and long-term follow-up. Limitations were a relatively homogeneous population that may not reflect the diversity of patient experiences. Conclusions These findings can be useful to providers and patients in understanding the effects of surgery and are reassuring that sexual function may, in fact, not be worsened by surgery.

Can we talk about sex? Feasibility of universal sexual health screening for BRCA1/2 patients

Abstract Background Risk-reducing salpingo-oophorectomy for ovarian cancer risk reduction in individuals with BRCA1/2 pathogenic variants can cause sexual dysfunction, yet sexual health discussions between patients and providers remain limited. Aim We describe the feasibility of universal sexual health screening and rates of sexual health dysfunction among individuals with BRCA1/2 pathogenic variants. Methods Patients with BRCA1/2 pathogenic variants presenting to an outpatient gynecologic oncology clinic from January 2022 to February 2023 were offered a sexual health screener. The screener combined a validated, single-item sexual dysfunction assessment with three additional questions exploring discussions of sexual health with healthcare providers, desire for information about sexual health, and preferred methods for delivery of information. Outcomes The primary outcome was the proportion of patients who completed the sexual health screener and the secondary outcomes included rate of sexual dysfunction and impact of patient characteristics on sexual dysfunction. Results Among 103 patients offered the sexual health screening, 100% completed it. Median age was 42 years (range 25-84). Eighty three (81%) patients self-identified as White, 32 (31%) patients had a history of cancer, 42 (41%) had undergone risk-reducing salpingo-oophorectomy, and 47 (46%) were pre-menopausal. Thirty seven (36%) patients screened positive for sexual dysfunction. Among patients with premature menopause following salpingo-oophorectomy, 6/15 (40%) on hormone replacement therapy reported sexual dysfunction versus 6/10 (60%) not on hormone replacement therapy (P = .43). Across all patients, 38 (37%) had never previously discussed sexual health concerns with a provider. There were no significant differences in sexual dysfunction rates based on any measured patient characteristics. Clinical Implications Universal sexual health screening for individuals with BRCA1/2 pathogenic variants is feasible and may provide an avenue for more in-depth discussion with at-risk patients, who may not have previously discussed this issue with their medical team. Strengths and Limitations Our study found that it was feasible to administer a sexual health screening tool among an at-risk patient population in a clinical setting. Generalizability may be limited due to the composition of our cohort, which was small, majority White and non-Hispanic, and from a single institution. Conclusion Providers should consider implementing standardized sexual health screening practices among patients with BRCA1/2 pathogenic variants. Research highlights

Quality of life after risk-reducing salpingo-oophorectomy in women with a pathogenic BRCA variant

Abstract Background Risk-reducing salpingo-oophorectomy (RRSO) is recommended to women with a pathogenic BRCA variant, but as a main side effect, RRSO could lead to an early onset of menopause. Aim To evaluate the impact of RRSO and preoperative menopausal status on menopausal symptoms, sexual functioning, and quality of life (QOL). Methods The study was conducted between November 2019 and April 2020. Women were included who tested positive for a pathogenic BRCA1/2 variant between 2015 and 2018. Depression levels, QOL, and global health status were measured and compared with those of women who opted against RRSO. Furthermore, women who underwent RRSO treatment were asked to report menopausal complaints that they experienced at 1 month postsurgery and any current complaints. Outcomes RRSO had no significant impact on QOL, but women who were premenopausal at the time of surgery reported more sexual complaints than postmenopausal women. Results In total, 134 carriers of a BRCA mutation were included: 90 (67%) underwent RRSO and 44 (33%) did not. At the time of the survey, neither the control nor experimental group experienced significant changes in QOL (b = –0.18, P = .59). Women who underwent RRSO reported a significantly lower global health status (b = –0.66, P = .05). Women who were premenopausal at the time of surgery were bothered more by sexual symptoms (b = 0.91, P = .19) but experienced fewer vasomotor complaints (b = –1.09, P = .13) than women who were postmenopausal at the time of RRSO. Clinical Implications The decrease of sexual functioning after RRSO should be an integral part of preoperative counseling because it is important for BRCA carriers, especially for premenopausal women. Strengths and Limitations Some strengths of the present study were the long follow-up, a high response rate, and the existence of a control group, whereas defining menopausal status by last menstrual bleeding and self-report of data (eg, breast cancer history) increased the risk of errors. Conclusion Our study indicated that women who underwent RRSO experienced no difference in QOL when compared with women without RRSO and that patients with premenopausal status seemed to be at higher risk to experience sexual complaints after surgery.

Clitoral reconstructive surgery in vulvar cancer patients: a qualitative study about motives, experiences, and outcomes

Abstract Background Vulvar cancer involving the clitoral region often requires radical excision, including (partial) resection of the clitoris, which can impair quality of life and sexual function, and although reconstructive flap surgery has long been used in patients with vulvar carcinoma to restore anatomy and overall function, clitoral-specific reconstructive procedures remain poorly described. Aim To evaluate patient motives, experiences, and outcomes following clitoral reconstruction in women with vulvar cancer. Methods Semi-structured interviews were conducted with vulvar cancer patients who underwent clitoral reconstructive (CR) surgery between 2019 and 2023 in a Dutch university medical center until data saturation was reached. Outcomes Motives, experiences, and outcomes as psychosexual functioning were analyzed using open coding. Results A total of 12 women participated in the study. Five principal themes were identified: preoperative motivation, the decision-making process, surgical outcomes, postoperative experiences, and the psychosocial impact. The primary motive for undergoing clitoral reconstruction was functional recovery. The majority, 10 out of 12 women, experienced functional recovery. The procedure contributed to an improved sense of femininity, which emphasizes the psychosocial impact of vulvar cancer surgery. Overall, the experiences with pre- and postoperative guidance were considered adequate, with the availability of written information and attention to open communication postoperatively on sexual functioning cited as areas for improvement. Clinical Implications These findings underscore the importance of addressing potential improvements for sexual health concerns in women diagnosed with vulvar cancer. Strength and Limitations A key strength of this study is its qualitative design, which enabled a nuanced exploration of patient motives, experiences, and functional outcomes following CR surgery. A limitation is that we did not include women who did not undergo clitoral reconstruction, preventing comparison of functional and psychosocial outcomes between groups. Conclusion Clitoral reconstructive surgery for women with vulvar cancer appears meaningful and has the potential to improve sexual function and overall well-being. These findings underscore the need for prospective studies to refine techniques and long-term outcomes.

Publisher

Oxford University Press (OUP)

ISSN

1743-6095